External Handoff Ingest

Entity: Blackrock Neurotech Date: 2026-05-08T22:31:27.457Z Source: External LLM (manual handoff)

Overall Assessment

(none)

Stage Notes

facts

• status: success
• items: 6
• summary: Blackrock Neurotech (originally Blackrock Microsystems) is the world's longest-established invasive BCI company, headquartered in Salt Lake City, Utah. Its core technology, the Utah Array, remains the global standard for intracortical recording. In 2024, the company sold a majority stake to the stablecoin issuer Tether for $200 million. In 2025-2026, the firm focused on the FDA approval of its MoveAgain home-use system and the development of Neuralace (10,000+ channels), while navigating a pending rebrand to Cogito Neurotech to distance itself from BlackRock Inc.

sources

• status: success
• items: 2
• summary: Primary documentation includes SEC filings for personnel transitions, Tether corporate announcements (2024-2025), FDA Breakthrough Device records, and the University of Utah's conflict of interest disclosures. Secondary coverage includes The Block, Reuters, and historical Salt Lake Tribune archives.

connections

• status: success
• items: 2
• summary: Blackrock Neurotech is the primary technical partner for the BrainGate Consortium and a longstanding contractor for DARPA and the NIH. Its investment syndicate includes Peter Thiel, Christian Angermayer, and majority owner Tether Evo. The company maintains a dual footprint with European headquarters in Hanover, Germany.

public_data_ingest

• status: success
• items: 1
• summary: Public data captures the transition to crypto ownership and recent executive turnover. Trademark filings (Cogito Neurotech) suggest an active rebrand strategy to resolve the naming conflict with BlackRock Inc.

contradictions

• status: success
• items: 1
• summary: The primary contradiction is the 'Blackrock Identity Crisis': the company is frequently confused with asset manager BlackRock Inc., leading to Bloomberg ticker errors and public disclaimers. Additionally, while the company markets its technology as 'FDA Cleared,' the clearance is restricted to 30-day hospital monitoring, creating a gap between its current regulatory status and its commercial home-use ambitions.

closed_loops

• status: success
• items: 1
• summary: The 'Neuro-Capture Loop': The Utah Array was developed via decades of public funding (NIH/DARPA) at a public university. This technology was then transferred to a private entity (Blackrock) where it was de-risked by federal SBIR grants and NIH-funded clinical trials. The resulting data established a 'gold standard' that allowed the founders to capture private crypto-capital (Tether) for a majority exit, while the company's future revenue remains dependent on government-regulated Medicare/Medicaid reimbursement models.

silences

• status: success
• items: 1
• summary: Blackrock Neurotech remains silent on the specific equity split following the Tether acquisition and has not provided an updated timeline for the MoveAgain commercial launch following the missed 2023 target.

voting_records

• status: empty_expected
• items: 0
• summary: no_data

donor_interests

• status: empty_expected
• items: 0
• summary: no_data

eo_metrics

• status: empty_expected
• items: 0
• summary: no_data

preparedness_scan

• status: empty_expected
• items: 0
• summary: no_data

home_stats_eligibility

• status: success
• items: 1
• summary: Utah-registered LLC; primary operations in Salt Lake City. European branch in Hanover, Germany providing EEA passporting rights for device distribution.

Ingest Summary

• Facts created: 6
• Sources created: 2
• Connections created: 0 (2 skipped)
• Stages marked: 0